Samsung Biologics Q3'26 operating profit rises to KRW 640.1 billion; Q3'26 revenue climbs 19% to KRW 1.49 trillion

PUBT · 1d ago
Samsung Biologics Q3'26 operating profit rises to KRW 640.1 billion; Q3'26 revenue climbs 19% to KRW 1.49 trillion
  • Samsung Biologics’ third-quarter 2026 operating profit rose to KRW 640.1 billion, while revenue climbed 19% year-over-year to KRW 1.49 trillion.
  • A KRW 3 trillion rights offering will fund strategic investments, including the planned PolyPeptide acquisition and future manufacturing capacity expansion.
  • Annual revenue growth guidance for 2026 increased to 20% from a previous range of 15–20%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610210300PR_NEWS_USPR_____CN77473) on October 21, 2026, and is solely responsible for the information contained therein.